<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03985410</url>
  </required_header>
  <id_info>
    <org_study_id>CS2514-2018-0003</org_study_id>
    <nct_id>NCT03985410</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers</brief_title>
  <official_title>A Randomized, Three Period Crossover Thorough QT (TQT) Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entasis Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entasis Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the effects of supratherapeutic ETX2514 plasma&#xD;
      concentrations on the heart rate-corrected QT interval (QTc).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2019</start_date>
  <completion_date type="Actual">July 24, 2019</completion_date>
  <primary_completion_date type="Actual">July 24, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The administration of ETX2514 and ETX2514 placebo will be double-blinded. Placebo and moxifloxacin (Treatment Period C) will be administered open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected change from Baseline in Fridericia-corrected QTc (QTcF) (ΔΔQTcF)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in heart rate (HR) (ΔHR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in QTcF (ΔQTcF)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the PR interval (ΔPR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the QRS interval (ΔQRS)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from Baseline in HR (ΔΔHR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from Baseline in PR (ΔΔPR)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Placebo-corrected change from Baseline in QRS (ΔΔQRS)</measure>
    <time_frame>Baseline; up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with categorical outliers for QTcF, HR, PR, and QRS</measure>
    <time_frame>up to Day 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-emergent changes of T-wave morphology and U-wave presence</measure>
    <time_frame>up to Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Acinetobacter Baumannii-calcoaceticus Complex Infections</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour intravenous (IV) infusion of 4 grams (g) of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 milligrams (mg) open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 3-hour IV infusion of placebo for ETX2514 and a single oral dose of 400 mg open-label moxifloxacin given at the end of the infusion (Treatment C), followed by a single 3-hour IV infusion of placebo for ETX2514 (Treatment B), followed by a single 3-hour IV infusion of 4 g of ETX2514 (supratherapeutic dose) (Treatment A). There will be 7 ± 2 days washout between treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETX2514</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Treatment Sequence ABC</arm_group_label>
    <arm_group_label>Treatment Sequence ACB</arm_group_label>
    <arm_group_label>Treatment Sequence BAC</arm_group_label>
    <arm_group_label>Treatment Sequence BCA</arm_group_label>
    <arm_group_label>Treatment Sequence CAB</arm_group_label>
    <arm_group_label>Treatment Sequence CBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, adult, male or female, 18-55 years of age, inclusive, at Screening&#xD;
&#xD;
          -  Continuous non-smoker who has not used nicotine-containing products for at least 3&#xD;
             months prior to the first dose&#xD;
&#xD;
          -  Must weigh at least 60 kilograms (kg) for males or 52 kg for females and have a body&#xD;
             mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/meters squared (m^2) at Screening.&#xD;
&#xD;
          -  Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs, or electrocardiograms (ECGs), as deemed&#xD;
             by the Principal Investigator (PI)&#xD;
&#xD;
          -  Women of childbearing potential (i.e., not post-menopausal or surgically sterilized)&#xD;
             must have a negative serum pregnancy test before randomization. Participating&#xD;
             heterosexual women of childbearing potential must be willing to consistently use 2&#xD;
             highly effective methods of contraception (i.e., condom with spermicide, combined oral&#xD;
             contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized&#xD;
             partner) from Screening until at least 30 days after administration of the last dose&#xD;
             of study drug; and&#xD;
&#xD;
          -  Non-childbearing women must have had a hysterectomy, surgical sterilization, or be&#xD;
             postmenopausal at least 12 months prior to Screening.&#xD;
&#xD;
          -  Male participants must be willing to use condoms with spermicide during sexual&#xD;
             intercourse from Screening until at least 90 days after administration of the last&#xD;
             dose of study drug.&#xD;
&#xD;
          -  Male participants with a vasectomy must have had the vasectomy at least 90 days prior&#xD;
             to randomization.&#xD;
&#xD;
          -  Male participants must agree not to donate sperm from the Screening period through 90&#xD;
             days after the last dose.&#xD;
&#xD;
          -  Understands the study procedures in the informed consent form and is willing and able&#xD;
             to comply with the protocol&#xD;
&#xD;
          -  Able to swallow tablets&#xD;
&#xD;
          -  Supine blood pressure between 90/40 millimeters of mercury (mmHg) and 140/90 mmHg&#xD;
             (inclusive) at Screening&#xD;
&#xD;
          -  No clinically significant history or presence of ECG findings as judged by the PI at&#xD;
             Screening and check-in, including each criterion as listed below:&#xD;
&#xD;
               1. Normal sinus rhythm (heart rate between 45 beats per minute [bpm] and 100 bpm&#xD;
                  inclusive);&#xD;
&#xD;
               2. Fridericia-corrected QTc (QTcF) interval &lt; 450 milliseconds (msec);&#xD;
&#xD;
               3. QRS interval ≤ 110 msec; and confirmed by manual over read if &gt; 110 msec;&#xD;
&#xD;
               4. PR interval ≤ 220 msec;&#xD;
&#xD;
               5. No electrographically significant abnormalities that might interfere with ECG&#xD;
                  analysis including evidence of a previous myocardial infarction (MI), significant&#xD;
                  left ventricular hypertrophy (LVH), flat T-waves (particularly in the inferior&#xD;
                  leads) or more than minor non-specific ST-T wave changes&#xD;
&#xD;
          -  Has serum potassium, calcium, and magnesium levels within the normal range at&#xD;
             Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is mentally or legally incapacitated or has significant emotional problems&#xD;
             at the time of the Screening visit or expected during the conduct of the study.&#xD;
&#xD;
          -  History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease in the opinion of the PI&#xD;
&#xD;
          -  History of any illness that, in the opinion of the PI, might confound the results of&#xD;
             the study or poses an additional risk to the participant by their participation in the&#xD;
             study&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse within the past 2 years prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  History or presence of hypersensitivity or idiosyncratic reaction to the study drugs,&#xD;
             related compounds, or inactive ingredients&#xD;
&#xD;
          -  History of significant multiple and/or severe allergies (e.g., latex allergy, band&#xD;
             aids, adhesive dressing, or medical tape), or has had an anaphylactic reaction or&#xD;
             significant intolerability to prescription or non-prescription drugs&#xD;
&#xD;
          -  Female participants who are pregnant or lactating&#xD;
&#xD;
          -  Positive urine drug or alcohol results at Screening or check-in&#xD;
&#xD;
          -  Positive results at Screening for human immunodeficiency virus (HIV), hepatitis B&#xD;
             surface antigen (HbsAg), or hepatitis C virus (HCV)&#xD;
&#xD;
          -  Unable to refrain from or anticipates the use of:&#xD;
&#xD;
               1. Any drug, including prescription and non-prescription medications (including&#xD;
                  antacids), herbal remedies, or vitamin supplements (especially those containing&#xD;
                  magnesium, aluminum, iron, or zinc) beginning 14 days prior to the first dose of&#xD;
                  study drug and throughout the study. Co-administration of ETX2514 and probenecid&#xD;
                  is prohibited.&#xD;
&#xD;
               2. Any drugs known to be significant inhibitors or inducers of cytochrome P450 (CYP)&#xD;
                  enzymes and/or permeability glycoprotein (P-gp), including St. John's Wort, for&#xD;
                  28 days prior to the first dose of study drug and throughout the study.&#xD;
&#xD;
          -  Has been on a diet incompatible with the on-study diet (including an extreme diet&#xD;
             which resulted in a significant weight change for whatever reason), in the opinion of&#xD;
             the PI, within the 28 days prior to the first dose of study drug, and throughout the&#xD;
             study&#xD;
&#xD;
          -  Donation of blood or significant blood loss more than 500 milliliters (mL) within 56&#xD;
             days prior to the first dose of study drug&#xD;
&#xD;
          -  Plasma donation within 7 days prior to the first dose of study drug&#xD;
&#xD;
          -  Has had surgery or any medical condition which may affect the absorption,&#xD;
             distribution, metabolism, or elimination of the study drug within 6 months prior to&#xD;
             the first dose, in the opinion of the PI&#xD;
&#xD;
          -  Participation in another clinical trial within 28 days prior to the first dose of&#xD;
             study drug. The 28-day window will be derived from the date of the last blood&#xD;
             collection or dosing, whichever is later, in the previous study to Day 1 of the&#xD;
             current study.&#xD;
&#xD;
          -  Participation in a previous clinical trial where participant received ETX2514&#xD;
&#xD;
          -  History or presence of:&#xD;
&#xD;
               1. hypokalemia, in the opinion of the PI;&#xD;
&#xD;
               2. risk factors for Torsades de Pointes (e.g., heart failure, cardiomyopathy, or&#xD;
                  family history of Long QT Syndrome);&#xD;
&#xD;
               3. sick sinus syndrome, second- or third-degree atrioventricular block, pulmonary&#xD;
                  congestion, cardiac arrhythmia, prolonged QT interval, or conduction&#xD;
                  abnormalities;&#xD;
&#xD;
               4. repeated or frequent vasovagal episodes:&#xD;
&#xD;
                    -  hypertension, angina, bradycardia, or severe peripheral arterial circulatory&#xD;
                       disorders;&#xD;
&#xD;
                    -  history or evidence of any of the following: MI, cardiac valvulopathy,&#xD;
                       cardiac surgery revascularization (coronary artery bypass grafting or&#xD;
                       percutaneous transluminal coronary angioplasty), unstable angina,&#xD;
                       cerebrovascular accident or stroke or transient ischemic attack (TIA),&#xD;
                       pacemaker; atrial fibrillation, flutter, or non-sustained or sustained&#xD;
                       ventricular tachycardia (VT); pulmonary arterial hypertension; unexplained&#xD;
                       syncope or syncope within the last 3 years regardless of etiology; and/or&#xD;
                       history of hypokalemia&#xD;
&#xD;
          -  Participant has a history within the last 6 months of frequent strenuous exercise,&#xD;
             and/or is unwilling to refrain from strenuous exercise from 7 days prior to baseline&#xD;
             Day -1 through the last Follow-Up Visit.&#xD;
&#xD;
          -  Participants who refused to abstain from caffeine-containing foods or caffeinated&#xD;
             beverages (e.g., coffee, tea, cola, energy drinks) for 7 days prior to Day -1 through&#xD;
             the last Follow-up Visit&#xD;
&#xD;
          -  Participants who refused to abstain from alcohol from 7 days prior to Day -1 through&#xD;
             the last Follow-Up Visit&#xD;
&#xD;
          -  Participants who refused to abstain from grapefruit-containing foods or beverages or&#xD;
             Seville orange-containing foods or beverages from 2 weeks prior to Day -1 through the&#xD;
             last Follow-Up Visit&#xD;
&#xD;
          -  Participant has consumed cruciferous vegetables (e.g., kale, broccoli, watercress,&#xD;
             collard greens, kohlrabi, Brussels sprouts, and mustard greens) or charbroiled meats&#xD;
             within 7 days prior to check-in through the last Follow-up Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaron Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acinetobacter baumannii-calcoaceticus</keyword>
  <keyword>complex infections</keyword>
  <keyword>ETX2514</keyword>
  <keyword>cardiac repolarization</keyword>
  <keyword>heart rate-corrected QT interval (QTc)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

